🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to all the team Baylor Scott & White Health for another highly successful Celebrating Women Luncheon. A huge thank you to LeAnn Rimes world famous singer, songwriter, actress and breast cancer advocate for supporting our breast cancer program in Texas. Over $40m now raised…

Updates today 1-2pm CST from the newly published SITC clinical practice guidelines for the use of IO across all GI malignancies. Please join myself, Dr Kristen Ciombor, Dr Scott Paulson and Dr Manish Shah.

Your superpower? Early detection. Watch the story that inspired Dak’s #MyCauseMyCleats and schedule your early screening today at bit.ly/40Z6NxW

Thank you to Dak Prescott and all the Dallas Cowboys for helping our team at Baylor Scott & White Health to raise awareness about the importance of cancer screening and early detection. Empowering you to live well #MyCauseMyCleats

Out in Nature Medicine our phase Ib study of neoadjuvant nivo/nivo+LAG-3 + chemoRT in esoph/GEJ cancer; linking ctDNA w path/immune responses and RFS. nature.com/articles/s4159… Elsa Anagnostou Johns Hopkins Thoracic Oncology Conquer Cancer, the ASCO Foundation #esophagealcancer 1/5

Clinical Trial Results Published in Nature Medicine Show Immunotherapy's Potential in ... - goo.gl/alerts/ccHd2U #GoogleAlerts

In a phase 1b trial in #GastroesophagealCancer, neoadjuvant nivolumab or nivolumab/relatlimab prior chemoradiotherapy were well tolerated and liquid biopsy analyses show that undetectable ctDNA was associated with longer survival Elsa Anagnostou Vincent Lam nature.com/articles/s4159…

📺 In a study by Ronan Kelly of @BSWHealth, ctDNA analyses showed that patients with undetectable ctDNA after treatment with #nivolumab had longer RFS and OS. 👉 Learn more about the trial that combined LAG-3 and PD-1 inhibitors for #esophagealcancer: buff.ly/4aX4PTb

First-Line Nivolumab and Relatlimab Plus Chemotherapy for Metastatic Gastric/GEJ: The Phase II RELATIVITY-060 Study now published in the JCO. Thank you to all the co-investigators and pts across 17 countries for participating in this important trial ascopubs.org/doi/full/10.12…

We are honored that the Charles A. Sammons Cancer Center at Baylor University Medical Center in Dallas has been ranked as one of the best cancer programs in the United States by USNWR U.S. News & World Report Baylor Scott & White Health

Can weight loss be a new medical tx for cancer? The TRIM-EBC trial will evaluate Tirzepatide (Zepbound) in women with breast cancer who are high risk for recurrence as a result of high BMI and ctDNA/MRD +ve disease Susan G. Komen OncoAlert ASCO OncLive.com news.bswhealth.com/en-US/releases…

The Texas Cancer Interception Institute aims to detect and intercept cancer at its earliest stages—when it is most treatable. Thank you to Ronan Kelly for his leadership, and to The York Family for their generosity in helping launch this initiative. bit.ly/3XlkWoy

Great speaking with Ronan Kelly (Baylor Scott & White Health) this afternoon at #ASCO25 who discussed: 🌟CheckMate 577 OS results & adjuvant nivolumab 🌟Abemaciclib + ramucirumab combo in metastatic GEA 🌟Optimal sequencing in gastroesophageal cancers 🌟AI-powered CT response assessment in